These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9242375)

  • 1. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
    Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
    Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.
    Iwashita T; Kato M; Murakami H; Asai N; Ishiguro Y; Ito S; Iwata Y; Kawai K; Asai M; Kurokawa K; Kajita H; Takahashi M
    Oncogene; 1999 Jul; 18(26):3919-22. PubMed ID: 10445857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
    Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
    Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
    Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
    Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
    Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
    Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
    Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
    Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
    Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
    Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
    Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
    Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.
    Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA
    Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests.
    Xue F; Yu H; Maurer LH; Memoli VA; Nutile-McMenemy N; Schuster MK; Bowden DW; Mao J; Noll WW
    Hum Mol Genet; 1994 Apr; 3(4):635-8. PubMed ID: 7915165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential.
    Cirafici AM; Salvatore G; De Vita G; Carlomagno F; Dathan NA; Visconti R; Melillo RM; Fusco A; Santoro M
    Endocrinology; 1997 Apr; 138(4):1450-5. PubMed ID: 9075701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.
    Reynolds L; Jones K; Winton DJ; Cranston A; Houghton C; Howard L; Ponder BA; Smith DP
    Oncogene; 2001 Jul; 20(30):3986-94. PubMed ID: 11494127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.
    Segouffin-Cariou C; Billaud M
    J Biol Chem; 2000 Feb; 275(5):3568-76. PubMed ID: 10652352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.
    Ito S; Iwashita T; Asai N; Murakami H; Iwata Y; Sobue G; Takahashi M
    Cancer Res; 1997 Jul; 57(14):2870-2. PubMed ID: 9230192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
    Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA
    Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.